Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 6% – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price rose 6% during trading on Friday . The company traded as high as $17.92 and last traded at $17.92. 302 shares traded hands during trading, a decline of 96% from the average daily volume of 6,879 shares. The stock had previously closed at $16.90.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Finally, B. Riley Financial began coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to MarketBeat.com, Ascentage Pharma Group International currently has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Trading Down 5.3%

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The business has a 50 day moving average price of $18.21 and a two-hundred day moving average price of $20.99.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million during the quarter. On average, analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.26 EPS for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Institutional investors have recently made changes to their positions in the stock. UBS Group AG lifted its position in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Finally, Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at approximately $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.